These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9864079)

  • 1. Buspirone augmentation of antidepressant therapy.
    Dimitriou EC; Dimitriou CE
    J Clin Psychopharmacol; 1998 Dec; 18(6):465-9. PubMed ID: 9864079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication augmentation after the failure of SSRIs for depression.
    Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
    N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression.
    Bouwer C; Stein DJ
    S Afr Med J; 1997 Apr; 87(4 Suppl):534-7, 540. PubMed ID: 9180827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.
    Fischer P; Tauscher J; Küfferle B; Kasper S
    Int Clin Psychopharmacol; 1998 Mar; 13(2):83-6. PubMed ID: 9669189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
    Landén M; Björling G; Agren H; Fahlén T
    J Clin Psychiatry; 1998 Dec; 59(12):664-8. PubMed ID: 9921700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
    Joffe RT; Schuller DR
    J Clin Psychiatry; 1993 Jul; 54(7):269-71. PubMed ID: 8335654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.
    Blier P; Bergeron R; de Montigny C
    Neuropsychopharmacology; 1997 May; 16(5):333-8. PubMed ID: 9109104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buspirone and imipramine for the treatment of major depression in the elderly.
    Schweizer E; Rickels K; Hassman H; Garcia-España F
    J Clin Psychiatry; 1998 Apr; 59(4):175-83. PubMed ID: 9590668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.
    Thase ME; Friedman ES; Biggs MM; Wisniewski SR; Trivedi MH; Luther JF; Fava M; Nierenberg AA; McGrath PJ; Warden D; Niederehe G; Hollon SD; Rush AJ
    Am J Psychiatry; 2007 May; 164(5):739-52. PubMed ID: 17475733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings.
    Gómez Gómez JM; Teixidó Perramón C
    J Clin Psychiatry; 2000 Apr; 61(4):285-9. PubMed ID: 10830150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible serotonin syndrome associated with buspirone added to fluoxetine.
    Manos GH
    Ann Pharmacother; 2000; 34(7-8):871-4. PubMed ID: 10928399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction.
    Spigset O; Adielsson G
    Int Clin Psychopharmacol; 1997 Jan; 12(1):61-3. PubMed ID: 9179637
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.
    Landén M; Eriksson E; Agren H; Fahlén T
    J Clin Psychopharmacol; 1999 Jun; 19(3):268-71. PubMed ID: 10350034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone.
    Onder E; Tural U
    J Affect Disord; 2003 Sep; 76(1-3):223-7. PubMed ID: 12943952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation strategies to increase antidepressant efficacy.
    Shelton RC
    J Clin Psychiatry; 2007; 68 Suppl 10():18-22. PubMed ID: 17900205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?
    Gaynes BN; Farley JF; Dusetzina SB; Ellis AR; Hansen RA; Miller WC; Stürmer T
    Depress Anxiety; 2011 Nov; 28(11):989-98. PubMed ID: 21898717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation strategies in depression 2000.
    Nelson JC
    J Clin Psychiatry; 2000; 61 Suppl 2():13-9. PubMed ID: 10714619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clomipramine augmentation in treatment-resistant depression.
    Amsterdam JD; García-España F; Rosenzweig M
    Depress Anxiety; 1997; 5(2):84-90. PubMed ID: 9262938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are gender differences important for the clinical effects of antidepressants?
    Hildebrandt MG; Steyerberg EW; Stage KB; Passchier J; Kragh-Soerensen P;
    Am J Psychiatry; 2003 Sep; 160(9):1643-50. PubMed ID: 12944340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.